148760-75-2

Basic information

• Product Name: 1-Boc-1H-pyrrolo[3,2-c]pyridine
• Synonyms: 1-Boc-1H-pyrrolo[3,2-c]pyridine;1H-Pyrrolo[3,2-c]pyridine-1-carboxylic acid, 1,1-diMethylethyl ester;1H-Pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 148760-75-2
• Molecular Formula: C₁₂H₁₄N₂O₂
• Molecular Weight: 218
• Mol File: 148760-75-2.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 339.3±34.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 7.02±0.30(Predicted)
• CAS DataBase Reference: 1-Boc-1H-pyrrolo[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-1H-pyrrolo[3,2-c]pyridine(148760-75-2)
• EPA Substance Registry System: 1-Boc-1H-pyrrolo[3,2-c]pyridine(148760-75-2)

Safety Data

• Hazardous Substances Data: 148760-75-2(Hazardous Substances Data)

Usage

General Description

1-Boc-1H-pyrrolo[3,2-c]pyridine is a chemical compound with the molecular formula C12H14N2O2. It is commonly used as a reagent in organic synthesis and pharmaceutical research. The "1-Boc" in its name denotes the presence of a tert-butoxycarbonyl (Boc) protecting group on the nitrogen atom. 1-Boc-1H-pyrrolo[3,2-c]pyridine is a heterocyclic molecule containing a pyrrolopyridine ring system, which makes it useful in the development of new drugs and bioactive molecules. Its unique structure and reactivity make it valuable in various chemical processes, and it has the potential for application in the pharmaceutical industry for the synthesis of targeted drug molecules.

Upstream product

• 271-34-1 5-azaindole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 211029-69-5 (3-Ethynyl-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 211029-70-8 (3-Trimethylsilanylethynyl-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 1074-98-2 3-methyl-4-nitropyridine N-oxide 
• 123367-22-6 (E)-N,N-dimethyl-2-(4-nitro-1-oxidopyridin-3-yl)ethenamine 
• 211029-67-3 (3-iodo-pyridin-4-yl)-carbamic acid tert-butyl ester 
• 1678-53-1 4-nitro-3-methylpyridine 
• 148760-47-8 3-Dimethylaminovinylene-4-nitropyridine 
• 148760-46-7 3-(4-Morpholinovinylene)-4-nitropyridine 1-oxide 
• 3005-27-4 3,4-dibromo-1-methyl-2,5-dihydropyrrole-2,5-dione 
• 877060-51-0 1-Boc-3-trimethylstannyl-5-azaindole 
• 271-29-4 6-azaindole 

Downstream Products

• 848410-13-9 tert-butyl (3aS,7aR)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[3,2-c]pyridine-1-carboxylate 
• 848410-13-9 tert-butyl rac-(3aR,7aS)-octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 271-34-1 5-azaindole 
• 1373492-30-8 5-(1-(2-chlorophenyl)-7-ethoxycarbonyl-7-methyloctyl)-4,5,6,7-tetrahydropyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester 
• 1373491-83-8 8-(2-chlorophenyl)-2,2 dimethyl-8-(1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-5-yl)-octanoic acid ethyl ester 
• 1373491-82-7 8-(2-chlorophenyl)-2,2-dimethyl-8-(1,4,6,7-tetrahydropyrrolo[3,2-c]pyridin-5-yl)-octanoic acid 
• 1147422-00-1 tert-butyl octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1373273-47-2 (1-(tert-butoxycarbonyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)boronic acid 
• 219834-81-8 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 

Relevant articles and documents

Transition metal catalyzed synthesis of 5-azaindoles

In an effort to develop synthetic procedures for the preparation of 2- substituted 5-azaindoles, the synthesis and cyclization reactions of acetylenic aminopyridines was explored. A novel method for the synthesis of 2-substituted 5-azaindoles via a transi

INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.